A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Clinical trial NCT07043725 · RECRUITING
Trial details
- NCT number
- NCT07043725
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-15
- Primary completion
- 2027-09-01
- Enrollment
- 544
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.